Immix Biopharma raises $150M to fund its AL amyloidosis therapy
What's the deal? Immix BiopharmaDealroom has a profile for this one. Try Dealroom →, a Los Angeles-based biotech focused on AL amyloidosis, has priced an underwritten public offering of 16.8 million shares at $8.94 each, raising $150M in gross proceeds. The Nasdaq-listed company plans to use the funds to advance its lead candidate, NXC-201, a CAR-T cell therapy targeting a rare and often fatal disease.
Morgan StanleyDealroom has a profile for this one. Try Dealroom → is lead book-running manager, with BofA SecuritiesDealroom has a profile for this one. Try Dealroom → as book-running manager. The offering is expected to close on or about May 22, 2026.
Why now? NXC-201 has built significant regulatory momentum. The US FDA has granted it both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy status, while also awarding Orphan Drug Designation — a label the European Medicines Agency has echoed. The therapy is currently being evaluated in a US multi-centre study (NEXICART-2) with a potentially registrational design, meaning positive results could support a regulatory filing.
Immix said the proceeds, combined with existing cash, should fund operations into mid-2028 — giving it a runway to hit key clinical milestones.
What could go wrong? CAR-T therapies are notoriously expensive and complex to manufacture, and clinical-stage biotechs face the ever-present risk of trial failure. AL amyloidosis is a small patient population, which limits the commercial opportunity even if NXC-201 succeeds. Dilution from the offering — roughly 16.8 million new shares — is also a near-term concern for existing shareholders.
The signal: Immix Biopharma sits at the late growth stageDealroom has a profile for this one. Try Dealroom →, and securing a $150M public offering led by Morgan StanleyDealroom has a profile for this one. Try Dealroom → — a corporate heavyweight — underscores that institutional capital is still flowing into clinical-stage rare disease programmes with clear regulatory tailwinds. For CAR-T specifically, the raise signals that investors are willing to fund the expensive manufacturing and trial infrastructure the modality demands, provided the regulatory pathway is sufficiently de-risked by designations like Breakthrough Therapy and RMAT.
Read more: immixbio.com
